Liver Transplant & Bile Duct Cancer | Dr. Zhou Guangwen (Hepatobiliary Surgery) | CMCS Shanghai

About Dr. Zhou Guangwen

Dr. Zhou Guangwen is a Senior Hepatobiliary Surgeon at Renji Hospital, Shanghai Jiao Tong University School of Medicine — one of China's foremost hepatobiliary surgery centres and a national reference institution for liver transplantation, bile duct malignancy, and complex pancreatic surgery. He is recognised for his expertise in liver transplantation for end-stage liver disease, combined hepatobiliary oncological resection, biliary reconstruction, and the multidisciplinary management of patients with concurrent hepatic failure and biliary malignancy. Dr. Zhou's practice is defined by the philosophy that end-stage liver disease and biliary cancer are not two separate problems requiring two separate solutions — they are a single pathological continuum that demands a single integrated surgical strategy, in which transplantation, oncological resection, and biliary reconstruction are planned and executed as one unified procedure. His department at Renji Hospital has established one of China's most comprehensive liver transplant programmes, integrating high-volume deceased-donor transplantation, precision biliary reconstruction, structured immunosuppression protocols, and multidisciplinary oncological surveillance into a unified care pathway for patients with complex combined hepatobiliary disease.

Case Overview

Mr. James Callahan (pseudonym), a 52-year-old Irish company executive based in Shanghai, presented with a three-month history of progressive jaundice, fatigue, and 5 kg weight loss, worsening acutely over one week. Laboratory findings confirmed decompensated hepatitis B cirrhosis — total bilirubin 385.6 μmol/L, albumin 28 g/L, INR 1.58, platelet count 68 × 10⁹/L — with CA19-9 markedly elevated at 1,250 U/mL. Enhanced CT and MRCP demonstrated a distal common bile duct carcinoma invading the pancreatic head and the portal vein and superior mesenteric vein confluence, superimposed on a cirrhotic liver with splenomegaly and ascites. A multidisciplinary team led by Dr. Zhou Guangwen determined that neither liver transplantation alone nor biliary resection alone could address both conditions — and that combined liver transplantation with en-bloc resection of the diseased bile duct and partial pancreatic head, followed by Roux-en-Y hepaticojejunostomy for biliary reconstruction, offered the only pathway to complete tumour clearance and hepatic replacement. At two weeks post-operatively, total bilirubin had normalised to 35.2 μmol/L and albumin had recovered to 35 g/L. MRCP at one month confirmed biliary anastomotic patency with no stricture or leak. No acute rejection episode occurred.

Patient Background

• Name / Nationality: Mr. James Callahan (pseudonym) — Irish; 52-year-old company executive based in Shanghai
• Age / Sex: 52-year-old male
• Chief Complaint: Progressive jaundice, fatigue, and weight loss for three months; acute deterioration for one week with pruritus and dark urine
• Symptoms: Skin and scleral icterus; generalised fatigue; anorexia; 5 kg weight loss over three months; pruritus; dark tea-coloured urine; no haematemesis or melaena
• Hepatic risk factors: Hepatitis B infection for 20 years — no regular antiviral therapy; alcohol consumption approximately 100 g per day for 20 years — dual aetiology cirrhosis
• Examination — general: Chronically ill appearance; cachectic; lethargic; severe skin and scleral jaundice; spider naevi and palmar erythema present
• Examination — abdomen: Flat abdomen; abdominal wall venous collaterals visible; liver not palpable below costal margin; spleen palpable 3 cm below costal margin, firm, non-tender; shifting dullness positive — ascites confirmed; Murphy's sign negative

Diagnostic Workup

Liver Function and Coagulation

• Total bilirubin (TBIL): 385.6 μmol/L — severely elevated; predominantly direct (DBIL 286.4 μmol/L) — confirming obstructive cholestasis
• Transaminases: ALT 125 U/L, AST 156 U/L — moderately elevated, consistent with hepatocellular injury superimposed on chronic cirrhosis
• Synthetic function: Albumin 28 g/L (severely reduced); PT 18.5 s, INR 1.58 — significantly impaired hepatic synthetic function; decompensated cirrhosis confirmed
• Haematology: Haemoglobin 95 g/L (anaemia); platelet count 68 × 10⁹/L — thrombocytopaenia consistent with hypersplenism from portal hypertension

Tumour Markers

• CA19-9: 1,250 U/mL — markedly elevated; highly suggestive of biliary malignancy in the context of biliary obstruction and the CT/MRCP findings
• CEA: 5.8 ng/mL — mildly elevated; non-specific

Hepatitis B Serology

• HBsAg positive, HBeAg positive, HBcAb positive — active hepatitis B replication; no prior antiviral therapy; dual aetiology cirrhosis (viral and alcoholic)

Abdominal Ultrasound

• Liver: Reduced volume; irregular surface; coarsened and heterogeneous parenchymal echogenicity — consistent with cirrhosis
• Spleen: Enlarged — splenomegaly consistent with portal hypertension
• Biliary system: Proximal common bile duct dilated to 1.2 cm internal diameter; distal common bile duct not clearly visualised — suggesting distal obstruction
• Ascites: Positive

Enhanced CT (Upper Abdomen)

• Liver: Diffuse cirrhotic morphology — nodular surface, caudate lobe hypertrophy, right lobe atrophy
• Biliary tumour: Irregular soft tissue mass in the distal common bile duct; avid enhancement on arterial phase — consistent with cholangiocarcinoma
• Vascular invasion: Tumour encasing the portal vein and superior mesenteric vein confluence — critical finding precluding standard Whipple resection without vascular reconstruction
• Pancreatic head: Tumour invasion of the pancreatic head confirmed

MRCP

• Biliary obstruction: Complete obstruction at the distal common bile duct; marked dilatation of the biliary system proximal to the obstruction — intrahepatic and extrahepatic bile ducts dilated
• Tumour delineation: Distal common bile duct mass clearly defined; findings consistent with CT — confirming cholangiocarcinoma with pancreatic head invasion

Dr. Zhou's pre-operative assessment: This patient has two diseases, and each one makes the other worse. The cirrhosis has destroyed the liver's reserve — the bilirubin is nearly 400, the albumin is 28, the INR is 1.58. That liver cannot recover on its own. But the bile duct cancer is causing the obstruction that is driving the bilirubin up, and the cancer has invaded the portal vein — which means a standard Whipple resection is not possible without vascular reconstruction, and vascular reconstruction in a cirrhotic patient with this degree of coagulopathy carries a mortality we cannot accept. The only operation that addresses both problems simultaneously is liver transplantation combined with en-bloc bile duct and partial pancreatic head resection. We replace the liver, we remove the tumour, and we reconstruct the biliary system in a single procedure. It is the most complex hepatobiliary operation we perform. But it is the only operation that gives this patient a chance.

Multidisciplinary Team Discussion and Treatment Strategy

The MDT convened by Dr. Zhou Guangwen included hepatobiliary surgery, hepatology, oncology, anaesthesiology, and critical care medicine. The consensus was that the patient's decompensated cirrhosis precluded any partial hepatic resection — the residual liver would not sustain life — and that the bile duct tumour's portal vein involvement precluded standard pancreaticoduodenectomy without the hepatic replacement that transplantation provides. Combined liver transplantation with en-bloc oncological resection was the only strategy that could address both conditions.

Donor matching: Deceased-donor liver from a brain-dead donor; strict matching and evaluation completed per national transplant protocols. Donor liver assessed for quality, vascular anatomy, and biliary anatomy before acceptance.

Surgical strategy: Single-stage combined procedure — explantation of the diseased liver with en-bloc resection of the diseased common bile duct, partial pancreatic head, and regional lymph nodes; orthotopic liver transplantation with sequential vascular anastomosis; biliary reconstruction via Roux-en-Y hepaticojejunostomy connecting the donor bile duct to a defunctioned jejunal limb.

Post-operative strategy: Triple immunosuppression protocol (tacrolimus, mycophenolate mofetil, corticosteroids); antiviral therapy for hepatitis B prophylaxis in the transplanted liver; broad-spectrum antibiotic prophylaxis; ICU-level monitoring for the immediate post-operative period.

Operative Procedure

Stage 1 — Donor Liver Procurement and Back-Table Preparation

Procurement: Donor liver retrieved from brain-dead donor under standard multi-organ procurement protocol. Meticulous preservation of hepatic artery, portal vein, inferior vena cava, and bile duct during procurement. Cold ischaemia time minimised.

Back-table preparation: Donor liver perfused with cold preservation solution and inspected on the back table. Excess adipose tissue and lymph nodes removed. Hepatic artery, portal vein, IVC, and bile duct anatomy confirmed. Liver texture, colour, and perfusion assessed — donor liver quality confirmed acceptable.

Stage 2 — Recipient Hepatectomy with En-Bloc Oncological Resection

Positioning and access: Supine position; general anaesthesia. Standard orthotopic liver transplant incision — bilateral subcostal with midline extension (Mercedes-Benz incision). Systematic division of hepatic ligaments and mobilisation of the liver.

Vascular dissection: Careful dissection and isolation of the suprahepatic IVC, infrahepatic IVC, portal vein, and hepatic artery. Given the tumour's involvement of the portal vein and superior mesenteric vein confluence, dissection at this level required meticulous technique to define the plane between tumour and vessel wall without entering the tumour or injuring the vascular structures that would be needed for the transplant anastomosis.

En-bloc oncological resection: The diseased common bile duct, partial pancreatic head, and regional lymph nodes were resected en-bloc with the explanted liver — removing the tumour in continuity with the organ it had invaded, rather than attempting a separate resection that would have required vascular reconstruction in a coagulopathic field. Regional lymphadenectomy performed. Resection margins assessed intraoperatively.

Haemostasis: Meticulous inspection of the resection bed; complete haemostasis achieved before proceeding to implantation.

Dr. Zhou's operative note: The critical moment in the explant is the portal vein dissection. The tumour has grown around the portal vein — not into the lumen, but around the wall. We need to free the portal vein from the tumour without entering the tumour and without injuring the vein, because that vein is the inflow for the new liver. If we damage it, we have no transplant. We work millimetre by millimetre in that plane. The en-bloc approach is what makes this possible — we are not trying to separate the tumour from the liver while the liver is still in place. We take them out together, and we define the margins on the back table where we have full visibility and no bleeding pressure.

Stage 3 — Orthotopic Liver Transplantation

Implantation sequence: Donor liver positioned in the right anatomical orientation in the hepatic fossa. Vascular anastomoses performed in sequence: suprahepatic IVC (continuous suture, no twist, no stenosis); infrahepatic IVC; portal vein. After each anastomosis, patency and haemostasis confirmed before proceeding.

Hepatic artery anastomosis: Donor and recipient hepatic arteries anastomosed under loupe magnification — arterial anastomosis is the highest-risk step for technical failure in liver transplantation; hepatic artery thrombosis is the most common cause of early graft loss. Intraoperative Doppler ultrasound confirmed arterial flow immediately after anastomosis.

Reperfusion: Portal vein clamp released; liver reperfused. Graft colour, texture, and bile production assessed — immediate bile production from the donor bile duct confirmed graft viability.

Stage 4 — Biliary Reconstruction: Roux-en-Y Hepaticojejunostomy

Indication for Roux-en-Y: The distal common bile duct had been resected en-bloc with the tumour — there was no recipient bile duct available for a duct-to-duct anastomosis. Roux-en-Y hepaticojejunostomy — connecting the donor bile duct to a defunctioned 60 cm jejunal limb — is the standard biliary reconstruction in this setting, providing a tension-free, reflux-free biliary-enteric anastomosis.

Jejunal limb preparation: A 60 cm Roux limb of jejunum divided and brought up to the hepatic hilum in a retrocolic position.

Hepaticojejunostomy: End-to-side anastomosis between the donor common bile duct and the Roux limb performed with interrupted absorbable sutures over a biliary stent. Anastomosis inspected for patency and absence of leak. Biliary stent left in situ to protect the anastomosis during the early healing period.

Closure and drainage: All anastomoses confirmed haemostatic and patent. Drains placed at the hepatic hilum, subhepatic space, and perihepatic region. Abdominal wall closed in layers.

Operative data: Total operative time approximately 480 minutes; intraoperative blood loss managed with cell salvage; no allogeneic transfusion required.

Post-operative Management and Outcomes

ICU and Early Recovery

• Immunosuppression: Triple protocol initiated — tacrolimus (target trough 8–12 ng/mL in the first month), mycophenolate mofetil, and prednisolone taper; doses adjusted based on daily tacrolimus levels and clinical response
• Hepatitis B prophylaxis: Antiviral therapy (entecavir) initiated immediately post-operatively to prevent hepatitis B recurrence in the donor liver
• Antibiotic prophylaxis: Broad-spectrum antibiotics continued for 48 hours; adjusted based on culture results
• Nutrition: Early parenteral nutrition; transition to enteral nutrition as bowel function recovered

Liver Function Recovery

• Post-operative day 7: Total bilirubin 120.5 μmol/L (down from 385.6 μmol/L); albumin 32 g/L (up from 28 g/L) — early graft function confirmed
• Post-operative day 14: Total bilirubin 35.2 μmol/L — near normalisation; albumin 35 g/L — synthetic function recovering; ALT and AST trending to normal range

Biliary System and Oncological Outcomes

• Jaundice resolution: Progressive resolution of skin and scleral icterus; pruritus resolved by week two; urine colour normalised
• Drain output: Drain fluid bilirubin levels monitored daily — no biliary leak detected; drains removed sequentially
• 1-month MRCP: Biliary system patent; Roux-en-Y anastomosis widely patent; no stricture, no leak, no biloma
• Rejection surveillance: No acute rejection episode; liver biopsy not required; immunosuppression maintained at protocol levels
• General recovery: Appetite and energy progressively restored; weight gain commenced; patient discharged to outpatient follow-up

Expert Commentary — Dr. Zhou Guangwen

1. The Intersection of Cirrhosis and Biliary Cancer: Why Neither Condition Can Be Treated in Isolation

End-stage liver disease and biliary malignancy are individually complex conditions. Their coexistence creates a pathological interaction that makes each condition worse and makes standard treatment of either condition impossible. The cirrhotic liver cannot tolerate partial resection — the residual liver volume after any meaningful hepatic resection would be insufficient to sustain life in a patient with Child-Pugh C disease. The biliary tumour cannot be resected by standard pancreaticoduodenectomy when it has invaded the portal vein — vascular reconstruction in a coagulopathic, hypoalbuminaemic patient with portal hypertension carries a perioperative mortality that is clinically unacceptable. The only operation that resolves both constraints simultaneously is combined liver transplantation with en-bloc oncological resection. Transplantation provides the hepatic replacement that makes the oncological resection survivable. The oncological resection provides the tumour clearance that makes the transplantation oncologically justified. Neither procedure is sufficient without the other.

2. En-Bloc Resection: Oncological Margins in the Context of Transplantation

The oncological principle of en-bloc resection — removing the tumour in continuity with the organ it has invaded, rather than attempting to separate them — is well established in surgical oncology. In the context of liver transplantation for biliary cancer, en-bloc resection has a specific technical advantage: the explanted liver provides a natural plane of dissection that allows the surgeon to work from the inside out, defining the tumour margins on the back table with full visibility and no haemorrhagic pressure. Attempting to resect the bile duct tumour separately from the liver — while the liver is still in situ and the portal hypertension is generating venous back-pressure — would create a haemorrhagic field that obscures the dissection plane and increases the risk of positive margins. The en-bloc approach eliminates this problem. The tumour comes out with the liver. The margins are assessed on the back table. The transplant proceeds into a clean field.

3. Roux-en-Y Hepaticojejunostomy: Biliary Reconstruction Without a Native Bile Duct

Biliary reconstruction is the step in liver transplantation that is most frequently associated with late complications — biliary stricture, bile leak, and cholangitis account for a significant proportion of post-transplant morbidity. In standard liver transplantation where the recipient bile duct is intact, duct-to-duct anastomosis is preferred because it preserves the sphincter of Oddi and allows endoscopic access to the biliary system if stricture develops. When the recipient bile duct has been resected — as in this case, where the distal common bile duct was removed en-bloc with the tumour — Roux-en-Y hepaticojejunostomy is the only option. The technical priorities are a tension-free anastomosis, an adequate lumen, and a Roux limb of sufficient length to prevent reflux of intestinal contents into the biliary system. A 60 cm Roux limb is the standard at our centre. The biliary stent protects the anastomosis during the critical first weeks of healing, when oedema at the anastomotic site is at its maximum and the risk of early stricture is highest.

4. Immunosuppression After Transplantation for Malignancy: Balancing Rejection and Recurrence

Immunosuppression after liver transplantation for malignancy presents a dilemma that does not exist in transplantation for benign disease. Adequate immunosuppression is essential to prevent rejection and protect the graft. But immunosuppression also suppresses the immune surveillance mechanisms that detect and eliminate residual tumour cells — and in a patient transplanted for biliary cancer, the risk of tumour recurrence is the dominant long-term threat to survival. The management of this dilemma requires individualised immunosuppression protocols that achieve adequate anti-rejection efficacy at the minimum dose consistent with oncological safety. At Renji Hospital, we use tacrolimus as the primary agent — targeting trough levels at the lower end of the therapeutic range in patients transplanted for malignancy — combined with mycophenolate mofetil and a rapidly tapered corticosteroid course. mTOR inhibitors such as everolimus are considered for conversion at three to six months, given their dual immunosuppressive and anti-tumour properties. The immunosuppression protocol is reviewed at every follow-up visit in the context of the oncological surveillance results — it is not a fixed protocol but a dynamic one, adjusted as the recurrence risk evolves over time.

How CMCS Shanghai Coordinated This Case

CMCS Shanghai supported Mr. Callahan and his family from initial presentation through post-transplant follow-up, including: urgent coordination of hepatobiliary surgery consultation with Dr. Zhou Guangwen at Renji Hospital, Shanghai Jiao Tong University with priority appointment scheduling given the severity of hepatic decompensation; bilingual review of all prior hepatology records, antiviral treatment history, and imaging with clinical summary for the MDT; coordination of enhanced CT, MRCP, and full laboratory workup with bilingual radiology and pathology report translation; bilingual interpretation throughout all MDT discussions involving hepatobiliary surgery, hepatology, oncology, anaesthesiology, and critical care; coordination of the deceased-donor transplant waitlist registration process with bilingual support for all consent and documentation requirements; real-time updates to the patient's wife and his hepatologist in Dublin during the operative period and ICU stay; ICU liaison support including daily bilingual clinical updates and coordination of family communication with the critical care team; immunosuppression protocol coordination including tacrolimus level monitoring, dose adjustment communication, and pharmacy coordination for tacrolimus, mycophenolate mofetil, and entecavir; antiviral therapy initiation and hepatitis B recurrence surveillance coordination; nutritional support coordination including dietitian referral and bilingual dietary guidance during recovery; one-month MRCP coordination with bilingual results communication to the patient's gastroenterologist in Ireland; oncological surveillance scheduling including CA19-9 monitoring, cross-sectional imaging, and results communication to the patient's oncologist overseas; and establishment of a long-term transplant surveillance protocol with annual liver biopsy scheduling, immunosuppression review, and direct liaison between Dr. Zhou's team and the patient's hepatologist and oncologist in the United Kingdom.

For international patients with end-stage liver disease, biliary malignancy, or complex combined hepatobiliary conditions requiring liver transplantation or advanced hepatobiliary surgery in Shanghai, Dr. Zhou Guangwen's team at Renji Hospital, Shanghai Jiao Tong University represents hepatobiliary surgery expertise at the international frontier — combining high-volume deceased-donor transplantation, en-bloc oncological resection, precision biliary reconstruction, and individualised immunosuppression to achieve hepatic replacement and tumour clearance in patients for whom no simpler operation is possible. CMCS ensures that expertise is accessible: in the patient's language, with overseas physicians and family informed at every step, from the first hepatology assessment through long-term transplant surveillance.

This case report is de-identified and published for educational purposes. All clinical details have been anonymized in accordance with patient privacy standards. CMCS Shanghai is a medical concierge service and does not provide direct medical care.